Evotec: What's Going On In 2026E And How To Value The Company
Source: SeekingAlpha
2026-03-10 14:24:57 ET
Evotec ( EVO ) has not been a good investment for me. While I would argue that Evotec has done well, especially towards the end of the year, today giving us the 2025 preliminary figures, the market does not seem to agree with this assessment, to put it mildly. The company, as I am writing, is down double digits in the NYSE pretrade and is down 13.7% on the native side for the ticker EVT on the ETR....
Read the full article on Seeking Alpha
For further details see:
Evotec: What's Going On In 2026E And How To Value The Company
Evotec SE
NASDAQ: EVO
EVO Trading
-8.27% G/L:
$2.495 Last:
96,967 Volume:
$2.56 Open:
EVO Latest News
January 08, 2026 01:50:00 am
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
January 02, 2026 12:30:00 am
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
December 08, 2025 01:20:00 am
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
December 04, 2025 02:50:00 am
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
EVO Stock Data
$320,181,806
73,171,742
N/A
9
N/A
Biotechnology & Life Sciences
Healthcare
DE
Hamburg
